A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells

Molecular Therapy

Volumn 19, Issue 1, 2011, Pages 211-217

  Song, Xiao Tong ^a,b   Turnis, Meghan E ^a,b   Zhou, Xiaoou ^a   Zhu, Wei ^a,c   Hong, Bang Xing ^d   Rollins, Lisa ^a   Rabinovich, Brian ^c   Chen, Si Yi ^d   Rooney, Cliona M ^a,b,e   Gottschalk, Stephen ^a,b,e  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; FLAGELLIN; OVALBUMIN; SHORT HAIRPIN RNA; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; EFFECTOR CELL; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

MUS;

EID: 78650871842     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.223     Document Type: Article

References (24)

1. Rosenberg, SA, Restifo, N P, Yang, JC, Morgan, RA and Dudley, ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
2. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modifcation of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
3. Dudley, ME and Rosenberg, SA (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666-675.
4. Hunder, NN, Wallen, H, Cao, J, Hendricks, DW, Reilly, JZ, Rodmyre, R et al. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
5. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virus-specifc T cells engineered to coexpress tumor-specifc receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
6. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
7. Ridgway, D (2003). The frst 1000 dendritic cell vaccinees. Cancer Invest 21: 873-886.
8. Nencioni, A, Grünebach, F, Schmidt, SM, Müller, MR, Boy, D, Patrone, F et al. (2008). The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65: 191-199. (Pubitemid 351200461)
9. Sekaly, RP (2008). The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
10. Lee, EG, Boone, DL, Chai, S, Libby, SL, Chien, M, Lodolce, JP et al. (2000). Failure to regulate TNF-induced NF-κB and cell death responses in A20-defcient mice. Science 289: 2350-2354.
11. Boone, DL, Turer, EE, Lee, EG, Ahmad, RC, Wheeler, MT, Tsui, C et al. (2004). The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060.
12. Hayashi, F, Smith, KD, Ozinsky, A, Hawn, TR, Yi, EC, Goodlett, DR et al. (2001). The innate immune response to bacterial fagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
13. Honko, AN and Mizel, SB (2005). Effects of fagellin on innate and adaptive immunity. Immunol Res 33: 83-101.
14. Gaucher, D, Therrien, R, Kettaf, N, Angermann, BR, Boucher, G, Filali-Mouhim, A, et al. (2008). Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
15. Lahiri, A, Das, P and Chakravortty, D (2008). Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26: 6777-6783.
16. Van Duin, D, Medzhitov, R and Shaw, AC (2006). Triggering TLR signaling in vaccination. Trends Immunol 27: 49-55.
17. Tosch, C, Geist, M, Ledoux, C, Ziller-Remi, C, Paul, S, Erbs, P et al. (2009). Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther 16: 310-319.
18. Song, XT, Evel-Kabler, K, Shen, L, Rollins, L, Huang, XF and Chen, SY (2008). A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 14: 258-265.
19. Park, MY, Kim, CH, Sohn, HJ, Oh, ST, Kim, SG and Kim, TG (2007). The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine 25: 7322-7330.
20. Darrah, PA, Patel, DT, De Luca, PM, Lindsay, RW, Davey, DF, Flynn, BJ et al. (2007). Multifunctional TH1 cells defne a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
21. Ren, W, Strube, R, Zhang, X, Chen, SY and Huang, XF (2004). Potent tumor-specifc immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res 64: 6645-6651.
22. Rabinovich, BA, Ye, Y, Etto, T, Chen, JQ, Levitsky, HI, Overwijk, WW et al. (2008). Visualizing fewer than 10 mouse T cells with an enhanced frefy luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 105: 14342-14346.
23. Ahmed, N, Salsman, VS, Yvon, E, Louis, CU, Perlaky, L, Wels, WS et al. (2009). Immunotherapy for osteosarcoma: genetic modifcation of T cells overcomes low levels of tumor antigen expression. Mol Ther 17: 1779-1787.
24. Song, XT, Evel-Kabler, K, Rollins, L, Aldrich, M, Gao, F, Huang, XF et al. (2006). An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3: e11.